[Amyloidosis: classification, diagnosis, and treatment]
Kiavasch M N Farid1,2, Stefan Schönland1,2, Norbert Blank1,2
1Medizinische Klinik V: Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
Innere Medizin (Heidelberg, Germany)
|June 8, 2026
Summary
Amyloidosis involves harmful protein deposits causing organ damage. Early diagnosis and targeted therapies, like chemotherapy or gene silencing, are key to managing this rare disease and preventing further dysfunction.
Area of Science:
- Medicine
- Biochemistry
- Genetics
Background:
- Amyloidosis is a group of rare protein-misfolding diseases.
- Characterized by insoluble fibrillar aggregate deposition, leading to organ damage.
- Deposits can be systemic or localized, with systemic forms linked to monoclonal gammopathies, inflammation, or hereditary factors.
Purpose of the Study:
- To review the current understanding of amyloidosis.
- To highlight advances in diagnosis and treatment.
- To emphasize the importance of early detection.
Main Methods:
- Literature review of recent advancements in amyloidosis.
- Analysis of diagnostic and therapeutic strategies.
- Focus on protein-misfolding mechanisms and genetic origins.
Main Results:
- Significant progress in diagnosing and managing amyloidosis over 25 years.
- Therapeutic strategies target the reduction of amyloidogenic protein production.
- Approaches include chemotherapy, anti-inflammatory agents, and gene-silencing.
Conclusions:
- Early diagnosis is critical for preventing irreversible organ dysfunction.
- Advances in treatment offer improved outcomes for patients.
- Continued research is vital for further understanding and combating amyloidosis.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...